Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.33 |
| ▸ | MYLK | Q15746 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648491 | 0.82 | IDO1 (0.44) | IDO1PDK2MEN1ALDH1A1HTT | |
| SCHEMBL27836355 | 0.81 | TSHR (0.35) | IDO1ALDH1A1TSHR | |
| SCHEMBL896087 | 0.77 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL6829818 | 0.77 | IDO1 (0.33) | IDO1MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL15260633 | 0.76 | PTPN1 (0.32) | IDO1TDP1 | |
| SCHEMBL9235134 | 0.76 | ABCB1 (0.50) | IDO1ADRA1ASMN1; SMN2 | |
| SCHEMBL734879 | 0.75 | KCNN4 (0.46) | IDO1PDK2MEN1ALDH1A1HTT | |
| Fluoride SCHEMBL1336323 | 0.74 | IDO1 (0.36) | IDO1PDK2MEN1ALDH1A1HTT | |
| SCHEMBL6218727 | 0.74 | L3MBTL1 (0.40) | MEN1ALDH1A1KMT2ANPSR1MAPT | |
| SCHEMBL8459673 | 0.73 | GABRA1 (0.42) | IDO1PDK2ALDH1A1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | claimed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | claimed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| US-5426106-A | Treatment of neurodegenerative diseases, schizophrenia, convulsions; selective non-competitive antagonists | MERCK SHARP & DOHME LIMITED (GB) | 1995-06-20 | — | — | US | claimed |
| US-5420155-A | Treatment of nervous system disorders with derivatives of 4-hydroxy-2-(1H)-pyrrolones such as strokes, antiischemic agents or cardiovascular disorders | MERCK SHARP & DOHME LTD. (GB) | 1995-05-30 | — | — | US | claimed |
| JP-59044345-A | — | — | None | — | — | JP | disclosed |
| US-11992012-B2 | Diaminotriazine compounds | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| CN-111743901-B | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20210186021-A1 | DIAMINOTRIAZINE COMPOUNDS | BASF SE (DE) | 2021-06-24 | — | — | US | disclosed |
| CN-111743901-A | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-2647644-B1 | 2'-O-MODIFIED RNA | WAVE LIFE SCIENCES JAPAN INC (JP) | 2020-09-09 | — | — | EP | disclosed |
| EP-0620812-A1 | QUINOLONE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1994-10-26 | — | — | EP | disclosed |
| US-5348962-A | Nervous system disorders; schizophrenia | MERCK SHARPE & DOHME LTD. | 1994-09-20 | — | — | US | disclosed |
| WO-1993011115-A2 | QUINOLONE DERIVATIVES AND THEIR USE AS NMDA AND AMPA RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
| EP-0481676-A1 | Hydroxyquinolone derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-04-22 | — | — | EP | disclosed |
| EP-0295839-A2 | Pyrimidine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-12-21 | — | — | EP | disclosed |
| JP-S5944345-A | PREPARATION OPTICAL ACTIVE BETA-AMINO ACID AND ITS INTERMEDIATE | TOYO JOZO CO LTD | 1984-03-12 | — | — | JP | disclosed |
| US-4001284-A | PRIMARY AMINES, 2,4-DIPHENOXY-5-SULFAMOYLBENZOIC ACID | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186021-A1 | DIAMINOTRIAZINE COMPOUNDS | DDT, DAZAP1, DDC | IDO1 113/4885PDK2 441/4885MEN1 3474/4885 |
| US-11992012-B2 | Diaminotriazine compounds | DDT, DAZAP1, DDC | IDO1 113/4885PDK2 441/4885MEN1 3474/4885 |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER1, PTGER4, PTGER2 | IDO1 2038/4885PDK2 1954/4885MEN1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.